Approvals, FDA Response Letters, New Drug Applications, Collaborations, and Positive Opinions Boost Major Drug Portfolios - Research Report on Pfizer, Merck, GSK, AstraZeneca, and Sanofi

NEW YORK, July 15, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Merck & Co. Inc. (NYSE: MRK), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), and Sanofi (NYSE: SNY). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On July 10, 2013, Pfizer Inc. (Pfizer) announced that it has received European approval for the expanded indication of its pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]). Being previously approved in the European Union (EU) for use in some specific age groups, the indication will now include adults aged 18 to 49 years for active immunization for the prevention of invasive disease caused by vaccine-type Streptococcus pneumoniae (S. pneumoniae). Emilio Emini, Ph.D., Chief Scientific Officer of Vaccine Research at Pfizer, said, "Prevenar 13 has been administered to millions of individuals around the world, and today's European approval for the expanded use of Prevenar 13 is a testament to Pfizer's continued commitment to developing innovative vaccines that can help prevent serious - and sometimes fatal - disease through every stage of life." The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/db02_PFE]

--

Merck & Co. Inc. Research Report

On July 1, 2013, Merck & Co. Inc. (Merck) announced that it has received a Complete Response Letter from the US Food and Drug Administration (FDA) regarding the Company's New Drug Application for suvorexant, an investigational medicine for the treatment of insomnia. Roger M. Perlmutter, M.D., Ph.D., President of Merck Research Laboratories, stated, "We will evaluate the requests outlined in the Complete Response Letter, and expect thereafter to work expeditiously with the FDA to make suvorexant available as a new treatment option for patients suffering from insomnia." The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/400f_MRK]

--

GlaxoSmithKline plc Research Report

On July 9, 2013, GlaxoSmithKline plc (GSK) announced that it has submitted supplemental New Drug Applications (NDA) to the US Food and Drug Administration for the use of dabrafenib, a BRAF inhibitor, in combination with trametinib, a MEK inhibitor. GSK reported that the supplemental applications were submitted to each of the currently approved NDAs, which will be for the use of each drug in combination with the other, for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or K mutation. The Company stated that the applications were based on data from a randomised Phase I/II study comparing dabrafenib monotherapy to combination therapy with dabrafenib and trametinib in patients with BRAF V600E and V600K mutation positive metastatic melanoma. GSK also reported that the drug administration of dabrafenib and trametinib in combination is investigational and not approved anywhere in the world. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/2737_GSK]

--

AstraZeneca PLC Research Report

On July 9, 2013, AstraZeneca PLC (AstraZeneca) announced that it has entered into an agreement for two-year collaboration with the University of Cambridge and Cancer Research UK. AstraZeneca reported that the agreement covers three pre-clinical and clinical oncology projects, and follows its recent announcement regarding its plan to establish its new UK-based global research and development centre and corporate headquarters at the Cambridge Biomedical Campus by 2016. Susan Galbraith, Head of AstraZeneca's Oncology Innovative Medicines Unit, commented, "These are the first research collaborations AstraZeneca has established with Cambridge-based partners since announcing our intention to build a strategic research and development centre on the Cambridge Biomedical Campus." Glabraith added, "It is fitting that the focus of these collaborations is on delivering new medicines for cancer because our Cambridge facility will become AstraZeneca's largest centre for oncology research. We look forward to having our scientists work side-by-side with some of the world's most distinguished medical institutions." The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/02c7_AZN]

--

Sanofi Research Report

On June 28, 2013, Sanofi announced that its subsidiary, Genzyme, received a positive opinion regarding the approval of LEMTRADA from the Committee for the Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). LEMTRADA (alemtuzumab) is under consideration for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. Sanofi reported that the CHMP had also issued a positive opinion, in early 2013, on new active substance designation (NAS) for AUBAGIO (teriflunomide). David Meeker, MD, President and CEO of Genzyme, stated, "Today's CHMP opinions set the stage for the approval of two important new treatment options for MS patients. Treatments to-date have addressed some of the unmet needs in MS, but still have limitations." Meeker continued, "Upon approval, physicians will have the ability to prescribe LEMTRADA for appropriate relapsing remitting patients based on their impressions of clinical or imaging characteristics regardless of duration of disease or treatment history. Expectations among the MS community are high for LEMTRADA and with today's positive CHMP opinion we are a step closer to making this very innovative treatment available for MS patients in Europe." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.WSReports.com/r/full_research_report/26eb_SNY]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports